JPRN-UMIN000004500已完成2 期
phase 2 trial of panitumumab and irinotecan in previously oxaliplatin and irinotecan refractory patients with colorectal cancer - phase 2 trial of panitumumab and irinotecan
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
研究概览
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) symptomatic brain metastasis 2) waterly diarrhea 3) Paralytic or mechanical bowel obstruction 4) severe infectious disease 5) severe plumonary disease (interstitial lung disease or plumonary fibrosis) 6) severe complications (uncontrolable diabetes, heart failure NYHA>=III, renal failure, liver failure) 7) Pregnant or lactating women or women of childbearing potential 8) carcinomatosis meningitis 9) peripheral neuropathy Grade>=3 10)Need to treatment with flucytosine, atazanavir sulfate 11) history of Grade>=3 hypersensitivity due to monoclonal antibody therapy 12) history of Grade>=3 hypersensitivity due to irinotecan 13) history of treatment of anti EGFR pathway 14) patients judged inappropriate for this study by physicians
研究者
相似试验
已完成
2 期
phase II study of panitumumab with irinotecan as third-line treatment for advanced colorectal cancer patientsmetastatic colorectal cancerJPRN-UMIN000005180Yokohama city university37
已完成
2 期
Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS MutationsMetastatic Colorectal CancerNCT00792363Vejle Hospital32
已完成
2 期
Phase II Study of Irinotecan and PanitumumabEsophageal CancerNCT00836277Weijing Sun, MD, FACP24
招募中
2 期
A Phase II trial of Panitumumab with irinotecan/S-1(IRIS) as 1st-line chemotherapy for KRAS wild type metastatic colorectal cancerKRAS wild type metastatic colorectal cancerJPRN-UMIN000008496Tohoku-Six Universities Research Group by Experts(T-SURGE)45
终止
2 期
Panitumumab and Irinotecan for Malignant GliomasMalignant Glioma of BrainNCT01017653Annick Desjardins16